BREAKING NEWS: Results released on new drug for lupus nephritis

This morning, Aurinia Pharmaceuticals announced positive results of a Phase IIB clinical study of voclosporin, a potential new therapy option for people with active lupus nephritis.  This is the first trial of a potential treatment for lupus nephritis to reach its primary endpoint: achieving complete remission in a statistically significant number of study participants. Lupus-related kidney disease (lupus nephritis) is one of the most serious and potentially life-threatening complications of lupus. The results of this trial are welcomed and exciting news for people with lupus and their doctors who are eager to have more tolerable and effective treatment options.   Read the full announcement.   We will continue to monitor developments with this trial and communicate information as it becomes available.   Sincerely,   Sandra C. Raymond President & CEO Lupus Foundation of America    You are receiving this email because you are subscribed to the Lupus Foundation of America's emails. If you would like to update your email preferences, please click here.

nonprofit software